Mortality in Castration Resistant Prostate Cancer Patients With and Without Pre‐Existing Cardiovascular Disease Receiving Oral Androgen Receptor Pathway Inhibitors
Pharmacoepidemiology and Drug Safety · 2026-07 · 35 (7)
DOI: 10.1002/pds.70405 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Pharmacoepidemiology and Drug Safety, online erschienen am 20.06.2026. Verfasst von Ibrahim M Asiri und 12 weiteren Autor:innen. Beteiligte Einrichtung: Saudi Food & Drug Authority, Riyadh, Saudi Arabia. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Cardiovascular Diseases, Androgen Receptor Antagonists. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCATS NIH HHS, National Center for Advancing Translational Sciences.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Men with castration‐resistant prostate cancer (CRPC) who have a pre‐existing history of cardiovascular disease (CVD) or other comorbidities are often excluded from clinical trials involving oral androgen receptor pathway inhibitors (ARPi). In this study, we compared all‐cause and prostate cancer‐specific mortality among CRPC patients, with and without a pre‐existing history of CVD, receiving ARPi compared to chemotherapy.
Methods
Men with CRPC were identified using the Surveillance, Epidemiology, and End Results‐Medicare Linked Database from 2004 to 2015. Patients were grouped into two analytical cohorts by drug use. Inverse probability treatment weights (IPTW)‐adjusted Cox models and Fine‐Gray subdistribution hazards models were used to evaluate associations between ARPi and chemotherapy, and between ENZ and AA for all‐cause mortality and cancer‐specific mortality separately.
Results
The study cohort included 1438 men with CRPC. Nearly 54.4% of patients had a pre‐existing history of CVD. Patients with a pre‐existing history of CVD had a higher incidence of all‐cause and prostate cancer‐specific mortality compared to patients without a history of CVD (all‐cause mortality: 69.7% vs. 59.3%, prostate cancer‐specific mortality: 56.0% vs. 49.5%, respectively). In the pre‐existing history of CVD cohort, the IPTW‐adjusted Cox model showed a significantly lower all‐cause mortality in patients who received APRi, enzalutamide, and abiraterone, versus chemotherapy (IPTW‐adjusted hazard ratio [AHR], 0.56; 95% Confidence Interval [CI], 0.48–0.64; p ‐value < 0.001). Further, the IPTW‐adjusted competing risk model showed significantly lower prostate cancer‐specific mortality in patients who received ARPi compared with those who received chemotherapy (IPTW‐AHR, 0.48; 95% CI, 0.41 to 0.57; p ‐value < 0.001). In the without pre‐existing history of CVD cohort, the adjusted Cox model showed significantly lower all‐cause mortality in patients who received APRi than those who received chemotherapy (IPTW‐AHR, 0.49; 95% CI, 0.41–0.60; p ‐value < 0.001). Whereas the IPTW‐adjusted competing risk model showed significantly lower prostate cancer‐specific mortality in patients who received ARPi compared with those who received chemotherapy (IPTW‐AHR, 0.52; 95% CI, 0.42–0.64; p ‐value < 0.001).
Conclusion
In this population‐based cohort of older men with castration‐resistant prostate cancer, treatment with oral androgen receptor pathway inhibitors was associated with lower estimated risks of all‐cause and prostate cancer–specific mortality compared with chemotherapy in patients with and without pre‐existing CVD. These findings add real‐world comparative effectiveness evidence for patient populations not well represented in randomized clinical trials; however, given the observational design and limitations of administrative data, residual confounding and unmeasured clinical differences may have influenced the results.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Saudi Food & Drug Authority, Riyadh, Saudi Arabia.
- Department of Quantitative Health Science, Mayo Clinic College of Medicine and Sciences, Scottsdale, Arizona, USA.
- Department of Radiation Oncology, University of Kansas, School of Medicine, Kansas City, Kansas, USA.
- Department of Urology, Emory University, School of Medicine, Atlanta, Georgia, USA.
- Department of Radiation Oncology, Mayo Clinic College of Medicine and Sciences, Phoenix, Arizona, USA.
- Division of Medical Oncology, Mayo Clinic College of Medicine and Sciences, Phoenix, Florida, USA.
ORCID-Profile: Ewan K Cobran
Förderung
- NCI NIH HHS
- NCATS NIH HHS
- National Center for Advancing Translational Sciences
Zitieren
APA
Asiri, I. M., Chen, R. C., Master, V., Mi, L., James, S. E., Moore, C., Bryce, A. H., Tilburt, J. C., Riaz, I. B., Naqvi, S. A. A., Afzal, U., Beach, S. R. H., & Cobran, E. K. (2026). Mortality in Castration Resistant Prostate Cancer Patients With and Without Pre‐Existing Cardiovascular Disease Receiving Oral Androgen Receptor Pathway Inhibitors. Pharmacoepidemiology and Drug Safety, 35(7). https://doi.org/10.1002/pds.70405
Vancouver
Asiri IM, Chen RC, Master V, Mi L, James SE, Moore C, et al. Mortality in Castration Resistant Prostate Cancer Patients With and Without Pre‐Existing Cardiovascular Disease Receiving Oral Androgen Receptor Pathway Inhibitors. Pharmacoepidemiology and Drug Safety. 2026;35(7). doi:10.1002/pds.70405
BibTeX
@article{Asiri2026,
author = {Asiri, Ibrahim M and Chen, Ronald C and Master, Viraj and Mi, Lanyu and James, Sarah E and Moore, Cassandra and Bryce, Alan H and Tilburt, Jon C and Riaz, Irbaz B and Naqvi, Syed Arsalan Ahmed and Afzal, Umar and Beach, Steven R H and Cobran, Ewan K},
title = {Mortality in Castration Resistant Prostate Cancer Patients With and Without Pre‐Existing Cardiovascular Disease Receiving Oral Androgen Receptor Pathway Inhibitors},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2026},
volume = {35},
number = {7},
doi = {10.1002/pds.70405}
}
EUVIMED